Compare Illumina, Inc. (ILMN) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Invesco Preferred ETF — how do they compare? Illumina, Inc. trades at $270.94 (market cap $39.95B), while Invesco Preferred ETF trades at $10.02 (market cap $3.60B). The key difference: Illumina, Inc. is far larger — about 11.1× Invesco Preferred ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Invesco Preferred ETF for 94 Days on average.
| ILMN | PGX | |
|---|---|---|
Market Cap | $39.95B | $3.60B |
Volume | 3,169,503 | 5,986,026 |
Sector | Health | — |
52-Week High | $293.69 | $11.61 |
52-Week Low | $91.00 | $9.97 |
Typical Hold Time | 83 Days | 94 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
PGX trades at $10.005, up 0.35% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios such as P/E and P/S, and no recent income statement or cash flow data is available. Recent corporate actions include dividend payments scheduled for 2026, but current fundamental metrics are not provided.
The outlook for PGX is cautious due to the absence of current financial data and bearish technical signals. Investment opportunities hinge on future earnings visibility and valuation clarity, while risks include potential earnings volatility and market sentiment shifts. Investors should await updated financial disclosures for a clearer assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
